An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced its participation in multiple healthcare conferences. On November 16, 2022, the company will present at both the Jefferies London Healthcare Conference and Stifel 2022 Healthcare Conference at 2:05 pm GMT and 1:15 pm ET, respectively. Additionally, Alnylam will engage in the Evercore ISI HealthCONx Conference on November 29, and the Piper Sandler Healthcare Conference on November 30. A live audio webcast of these events will be available on Alnylam's website.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London
Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:15 pm ET at the Lotte New York Palace Hotel in New York City
Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022 at 1:50 pm ET being held virtually
Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 9:30 am ET at the Lotte New York Palace Hotel in New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.